1. Expanding access to early phase trials: the CATCH-UP.2020 experience
- Author
-
Baranda, Joaquina C, Diaz, Francisco J, Rubinstein, Larry, Shields, Anthony F, Dayyani, Farshid, Mehta, Amitkumar, Mehnert, Janice M, Trent, Jonathan, Mabaera, Rodwell, Mooney, Margaret, Moscow, Jeffrey A, Doroshow, James, Waters, Brittany, Ivy, Percy, Gore, Steven D, and Thomas, Alexandra
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Minority Health ,Clinical Research ,Social Determinants of Health ,Clinical Trials and Supportive Activities ,Patient Safety ,Cancer ,Health Disparities ,Rural Health ,Behavioral and Social Science ,Humans ,COVID-19 ,Ethnicity ,Minority Groups ,Neoplasms ,Pandemics ,Clinical Trials as Topic ,Oncology and carcinogenesis - Abstract
BackgroundDisparities in cancer outcomes persist for underserved populations; one important aspect of this is limited access to promising early phase clinical trials. To address this, the National Cancer Institute-funded Create Access to Targeted Cancer Therapy for Underserved Populations (CATCH-UP.2020) was created. We report the tools developed and accrual metrics of the initial year of CATCH-UP.2020 with a focus on racial, ethnic, geographic, and socioeconomically underserved populations.MethodsCATCH-UP.2020 is a P30 supplement awarded to 8 National Cancer Institute-designated cancer centers with existing resources to rapidly open and accrue to Experimental Therapeutics Clinical Trials Network (ETCTN) trials with emphasis on engaging patients from underserved populations. Sites used patient-based, community-based, investigator-based, and program-based tools to meet specific program goals.ResultsFrom September 2020 to August 2021, CATCH-UP.2020 sites opened 45 ETCTN trials. Weighted average trial activation time for the 7 sites reporting this was 107 days. In the initial year, sites enrolled 145 patients in CATCH-UP.2020 with 68 (46.9%) representing racial, ethnic, rural, and socioeconomically underserved populations using the broader definition of underserved encompassed in the grant charge. During the initial year of CATCH-UP.2020, a time impacted by the COVID-19 pandemic, 15.8% (66 of 417) and 21.4% (31 of 145) of patients enrolled to ETCTN trials at network and at CATCH-UP sites, respectively, were from racial and ethnic minority groups, a more limited definition of underserved for which comparable data are available.ConclusionTargeted funding accelerated activation and accrual of early phase trials and expanded access to this therapeutic option for underserved populations.
- Published
- 2023